Pathways to motor neuron degeneration in transgenic mouse models

Biochimie

Volumn 84, Issue 11, 2002, Pages 1151-1160

  Robertson, Janice ^a   Kriz, Jasna ^a   Nguyen, Minh Dang ^a   Julien, Jean Pierre ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Amyotrophic lateral sclerosis; Cdk5; Motor neuron disease; Neurofilaments; Superoxide dismutase

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CASPASE INHIBITOR; CHAPERONE; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LYSINE ACETYLSALICYLATE; MINOCYCLINE; NEUROFILAMENT PROTEIN; NITRIC OXIDE; PERIPHERIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P25; RILUZOLE; SALICYLIC ACID; SUPEROXIDE DISMUTASE; TAU PROTEIN; TETRACYCLINE; TUMOR NECROSIS FACTOR; UBIQUITIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ASTROCYTOSIS; AXONAL INJURY; CELL AGGREGATION; CELL DEATH; CELL ORGANELLE; CELL PROTECTION; COMPLEX FORMATION; CONFERENCE PAPER; CYTOSKELETON; DRUG EFFECT; DRUG TOLERABILITY; FAMILIAL DISEASE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; INTERMEDIATE FILAMENT; MICROGLIA; MOTONEURON; MOTOR NEURON DISEASE; MOUSE; MOUSE MUTANT; NERVE CELL DEGENERATION; NEUROFILAMENT; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PERIKARYON; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

ADULT; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, NEUROLOGICAL; MOTOR NEURON DISEASE; NERVE DEGENERATION; NERVE TISSUE PROTEINS; SUPEROXIDE DISMUTASE;

MUS MUSCULUS;

EID: 0036880782     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(02)00025-1     Document Type: Conference Paper

References (112)

1. M.J. Strong, Progress in clinical neurosciences: The evidence for ALS as a multisystems disorder of limited phenotypic expression, Can. J. Neurol. Sci. 28 (2001) 283-298.
2. D.R. Rosen, T. Siddique, D. Patterson, D.A. Figlewicz, P. Sapp, A. Hentati, D. Donaldson, J. Goto, J.P. O'Regan, H.X. Deng, et al., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature 362 (1993) 59-62.
3. D.W. Cleveland, From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS, Neuron 24 (1999) 515-520.
4. J.P. Julien, Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded, Cell 104 (2001) 581-591.
5. S. Hadano, C.K. Hand, H. Osuga, Y. Yanagisawa, A. Otomo, R.S. Devon, N. Miyamoto, J. Showguchi-Miyata, Y. Okada, R. Singaraja, D.A. Figlewicz, T. Kwiatkowski, B.A. Hosler, T. Sagie, J. Skaug, J. Nasir, R.H. Brown Jr, S.W. Scherer, G.A. Rouleau, M.R. Hayden, J.E. Ikeda, A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2, Nat. Genet. 29 (2001) 166-173.
6. Y. Yang, A. Hentati, H.X. Deng, O. Dabbagh, T. Sasaki, M. Hirano, W.Y. Hung, K. Ouahchi, J. Yan, A.C. Azim, N. Cole, G. Gascon, A. Yagmour, M. Ben-Hamida, M. Pericak-Vance, F. Hentati, T. Siddique, The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis, Nat. Genet. 29 (2001) 160-165.
7. D.A. Figlewicz, A. Krizus, M.G. Martinoli, V. Meininger, M. Dib, G.A. Rouleau, J.P. Julien, Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis, Hum. Mol. Genet. 3 (1994) 1757-1761.
8. J. Tomkins, P. Usher, J.Y. Slade, P.G. Ince, A. Curtis, K. Bushby, PJ. Shaw, Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS), Neuroreport 9 (1998) 3967-3970.
9. A. Al-Chalabi, P.M. Andersen, P. Nilsson, B. Chioza, J.L. Andersson, C. Russ, C.E. Shaw, J.F. Powell, P.N. Leigh, Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis, Hum. Mol. Genet. 8 (1999) 157-164.
10. K. Rooke, D.A. Figlewicz, F.Y. Han, G.A. Rouleau, Analysis of the KSP repeat of the neurofilament heavy subunit in familiar amyotrophic lateral sclerosis, Neurology 46 (1996) 789-790.
11. J.D. Vechio, L.I. Bruijn, Z. Xu, R.H. Brown Jr, D.W. Cleveland, Sequence variants in human neurofilament proteins: Absence of linkage to familial amyotrophic lateral sclerosis, Ann. Neurol. 40 (1996) 603-610.
12. I.V. Mersiyanova, A.V. Perepelov, A.V. Polyakov, V.F. Sitnikov, E.L. Dadali, R.B. Oparin, A.N. Petrin, O.V. Evgrafov, A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene, Am. J. Hum. Genet. 67 (2000) 37-46.
13. P. De Jonghe, I.V. Mersiyanova, E. Nelis, J. Del Favero, J.J. Martin, C. Van Broeckhoven, O.V. Evgrafov, V. Timmerman, Further evidence that neurofilament light chain mutations can cause Charcot-Marie Tooth disease type 2E, Ann. Neurol. 49 (2001) 245-249.
14. C. Lavedan, S. Buchholtz, R.L. Nussbaum, R.L. Albin, M.H. Polymeropoulos, A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration, Neurosci. Lett. 322 (2002) 57-61.
15. E. Fuchs, D.W. Cleveland, A structural scaffolding of intermediate filaments in health and disease, Science 279 (1998) 514-519.
16. J.P. Julien, W.E. Mushynski, Neurofilaments in health and disease, Prog. Nucleic Acid Res. Mol. Biol. 61 (1998) 1-23.
17. T. Gotow, Neurofilaments in health and disease, Med. Electron Microsc. 33 (2000) 173-199.
18. J.S. Pachter, R.K. Liem, Alpha-Internexin, a 66-kD intermediate filament-binding protein from mammalian central nervous tissues, J. Cell Biol. 101 (1985) 1316-1322.
19. C.L. Chien, R.K. Liem, Characterization of the mouse gene encoding the neuronal intermediate filament protein alpha-internexin, Gene 149 (1994) 289-292.
20. M.M. Portier, B. De Nechaud, F. Gros, Peripherin, a new member of the intermediate filament protein family, Dev. Neurosci. 6 (1983) 335-344.
21. L.M. Parysek, R.D. Goldman, Distribution of a novel 57 kDa intermediate filament (IF) protein in the nervous system, J. Neurosci. 8 (1988) 555-563.
22. M. Escurat, K. Djabali, M. Gumpel, F. Gros, M.M. Portier, Differential expression of two neuronal intermediate-filament proteins, peripherin and the low-molecular-mass neurofilament protein (NF-L), during the development of the rat, J. Neurosci. 10 (1990) 764-784.
23. M.M. Oblinger, J. Wong, L.M. Parysek, Axotomy-induced changes in the expression of a type III neuronal intermediate filament gene, J. Neurosci. 9 (1989) 3766-3775.
24. C.M. Troy, N.A. Muma, L.A. Greene, D.L. Price, M.L. Shelanski, Regulation of peripherin and neurofilament expression in regenerating rat motor neurons, Brain Res. 529 (1990) 232-238.
25. A. Hirano, I. Nakano, L.T. Kurland, D.W. Mulder, P.W. Holley, G. Saccomanno, Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis, J. Neuropathol Exp. Neurol. 43 (1984) 471-480.
26. G.A. Rouleau, A.W. Clark, K. Rooke, A. Pramatarova, A. Krizus, O. Suchowersky, J.P. Julien, D. Figlewicz, SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis, Ann. Neurol. 39 (1996) 128-131.
27. M. Corbo, A.P. Hays, Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease, J. Neuropathol. Exp. Neurol. 51 (1992) 531-537.
28. N.K. Wong, B.P. He, M.J. Strong, Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS), J. Neuropathol. Exp. Neurol. 59 (2000) 972-982.
29. Q. Zhu, S. Couillard-Despres, J.P. Julien, Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments, Exp. Neurol. 148 (1997) 299-316.
30. S. Ackerley, A.J. Grierson, J. Brownlees, P. Thornhill, B.H. Anderton, P.N. Leigh, C.E Shaw, C.C. Miller, Glutamate slows axonal transport of neurofilaments in transfected neurons, J. Cell Biol. 150 (2000) 165-176.
31. J.P. Crow, Y.Z. Ye, M. Strong, M. Kirk, S. Barnes, J.S. Beckman, Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L, J. Neurochem. 69 (1997) 1945-1953.
32. S.M. Chou, H.S. Wang, A. Taniguchi, R. Bucala, Advanced glycation end products in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis, Mol. Med. 4 (1998) 324-332.
33. M.J. Strong, M.M. Sopper, J.P. Crow, W.L. Strong, J.S. Beckman, Nitration of the low molecular weight neurofilament is equivalent in sporadic amyotrophic lateral sclerosis and control cervical spinal cord, Biochem. Biophys. Res. Commun 248 (1998) 157-164.
34. Q. Zhu, M. Lindenbaum, F. Levavasseur, H. Jacomy, J.P. Julien, Disruption of the NF-H gene increases axonal microtubule content and velocity of neurofilament transport: Relief of axonopathy resulting from the toxin beta, beta'-iminodipropionitrile, J. Cell Biol. 143 (1998) 183-193.
35. M.V. Rao, M.K. Houseweart, T.L. Williamson, T.O. Crawford, J. Folmer, D.W. Cleveland, Neurofilament-dependent radial growth of motor axons and axonal organization of neurofilaments does not require the neurofilament heavy subunit (NF-H) or its phosphorylation, J. Cell Biol. 143 (1998) 171-181.
36. G.A. Elder, V.L. Friedrich Jr, C. Kang, P. Bosco, A. Gourov, P.H. Tu, B. Zhang, V.M. Lee, R.A. Lazzarini, Requirement of heavy neurofilament subunit in the development of axons with large calibers, J. Cell Biol. 143 (1998) 195-205.
37. G.A. Elder, V.L. Friedrich Jr, A. Margita, R.A. Lazzarini, Age-related atrophy of motor axons in mice deficient in the mid-sized neurofilament subunit, J. Cell Biol. 146 (1999) 181-192.
38. H. Jacomy, Q. Zhu, S. Couillard-Despres, J.M. Beaulieu, J.P. Julien, Disruption of type IV intermediate filament network in mice lacking the neurofilament medium and heavy subunits, J. Neurochem. 73 (1999) 972-984.
39. F. Levavasseur, Q. Zhu, J.P. Julien, No requirement of alpha-internexin for nervous system development and for radial growth of axons, Brain Res. Mol. Brain Res. 69 (1999) 104-112.
40. J. Kriz, Q. Zhu, J.P. Julien, A.L. Padjen, Electrophysiological properties of axons in mice lacking neurofilament subunit genes: Disparity between conduction velocity and axon diameter in absence of NF-H, Brain Res. 885 (2000) 32-44.
41. Z. Xu, L.C. Cork, J.W. Griffin, D.W. Cleveland, Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease, Cell 73 (1993) 23-33.
42. F. Cote, J.F. Collard, J.P. Julien, Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis, Cell 73 (1993) 35-46.
43. P.C. Wong, J. Marszalek, T.O. Crawford, Z. Xu, S.T. Hsieh, J.W. Griffin, D.W. Cleveland, Increasing neurofilament subunit NF-M expression reduces axonal NF-H, inhibits radial growth, and results in neurofilamentous accumulation in motor neurons, J. Cell. Biol. 130 (1995) 1413-1422.
44. J. Kriz, J. Meier, J.P. Julien, A.L. Padjen, Altered ionic conductances in axons of transgenic mouse expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis, Exp. Neurol. 163 (2000) 414-421.
45. J.M. Beaulieu, H. Jacomy, J.P. Julien, Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit. J. Neurosci. 20 (2000) 5321-5328.
46. J. Meier, S. Couillard-Despres, H. Jacomy, C. Gravel, J.P. Julien, Extra neurofilament NF-L subunits rescue motor neuron disease caused by overexpression of the human NF-H gene in mice, J. Neuropathol. Exp. Neurol. 58 (1999) 1099-1110.
47. M.K. Lee, J.R. Marszalek, D.W. Cleveland, A mutant neurofilament subunit causes massive, selective motor neuron death: Implications for the pathogenesis of human motor neuron disease, Neuron 13 (1994) 975-988.
48. M.K. Houseweart, D.W. Cleveland, Bcl-2 overexpression does not protect neurons from mutant neurofilament-mediated motor neuron degeneration. J. Neurosci. 19 (1999) 6446-6456.
49. J.M. Beaulieu, M.D. Nguyen, J.P. Julien, Late onset death of motor neurons in mice overexpressing wild-type peripherin, J. Cell Biol. 147 (1999) 531-544.
50. C. Bergeron, K. Beric-Maskarel, S. Muntasser, L. Weyer, M.J. Somerville, M.E. Percy, Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons, J. Neuropathol. Exp. Neurol. 53 (1994) 221-230.
51. J. Robertson, J.M. Beaulieu, M.M. Doroudchi, H.D. Durham, J.P. Julien, W.E. Mushynski, Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha, J. Cell Biol. 155 (2000) 217-226.
52. E. Sterneck, D.R. Kaplan, P.F. Johnson, Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells, J. Neurochem. 67 (1996) 1365-1374.
53. M.J. Lecomte, M. Basseville, F. Landon, V. Karpov, M. Fauquet, Transcriptional activation of the mouse peripherin gene by leukemia inhibitory factor: Involvement of STAT proteins, J. Neurochem. 70 (1998) 971-982.
54. J.S. Beckman, J.P. Crow, Pathological implications of nitric oxide, superoxide and peroxynitrite formation, Biochem. Soc. Trans. 21 (1993) 330-334.
55. M. Wiedau-Pazos, J.J. Goto, S. Rabizadeh, E.B. Gralla, J.A. Roe, M.K. Lee, J.S. Valentine, D.E. Bredesen, Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis, Science 271 (1996) 515-518.
56. L.I. Bruijn, M.K. Houseweart, S. Kato, K.L. Anderson, S.D. Anderson, E. Ohama, A.G. Reaume, R.W. Scott, D.W. Cleveland, Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1, Science 281 (1998) 1851-1854.
57. J.R. Subramaniam, W.E. Lyons, J. Liu, T.B. Bartnikas, J. Rothstein, D.L. Price, D.W. Cleveland, J.D. Gitlin, P.C. Wong, Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading, Nat. Neurosci. 5 (2002) 301-307.
58. H.D. Durham, J. Roy, L. Dong, D.A. Figlewicz, Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS, J. Neuropathol. Exp. Neurol. 56 (1997) 523-530.
59. J.A. Johnston, M.J. Dalton, M.E. Gurney, R.R. Kopito, Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis, Proc. Natl. Acad. Sci. USA 97 (2000) 12571-12576.
60. D.L. Price, P.C. Wong, A.L. Markowska, M.K. Lee, G. Thinakaren, D.W. Cleveland, S.S. Sisodia, D.R. Borchelt, The value of transgenic models for the study of neurodegenerative diseases, Ann. NY Acad. Sci. 920 (2000) 179-191.
61. J. Wang, G. Xu, D.R. Borchelt, High molecular weight complexes of mutant superoxide dismutase 1: Age-dependent and tissue-specific accumulation, Neurobiol. Dis. 9 (2002) 139-148.
62. B. Zhang, P. Tu, F. Abtahian, J.Q. Trojanowski, V.M. Lee, Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation, J. Cell Biol. 139 (1997) 1307-1315.
63. T.L. Williamson, D.W. Cleveland, Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons, Nat. Neurosci. 2 (1999) 50-56.
64. M.E. Gurney, H. Pu, A.Y. Chiu, M.C. Dal Canto, C.Y. Polchow, D.D. Alexander, J. Caliendo, A. Hentati, Y.W. Kwon, H.X. Deng, et al., Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation, Science 264 (1994) 1772-1775.
65. P.H. Tu, P. Raju, K.A. Robinson, M.E. Gurney, J.Q. Trojanowski, V.M. Lee, Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions, Proc. Natl. Acad. Sci. USA 93 (1996) 3155-3160.
66. S. Couillard-Despres, Q. Zhu, P.C. Wong, D.L. Price, D.W. Cleveland, J.P. Julien, Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase, Proc. Natl. Acad. Sci. USA 95 (1998) 9626-9630.
67. T.L. Williamson, L.I. Bruijn, Q. Zhu, K.L. Anderson, S.D. Anderson, J.P. Julien, D.W. Cleveland, Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant, Proc. Natl. Acad. Sci. USA 95 (1998) 9631-9636.
68. J. Kong, Z. Xu, Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis, Neurosci. Lett. 281 (2000) 72-74.
69. M.D. Nguyen, R.C. Lariviere, J.P. Julien, Reduction of axonal caliber does not alleviate motor neuron disease caused by mutant superoxide dismutase 1, Proc. Natl. Acad. Sci. USA 97 (2000) 12306-12311.
70. M.D. Nguyen, R.C. Lariviere, J.P. Julien, Deregulation of Cdk5 in a mouse model of ALS: Toxicity alleviated by perikaryal neurofilament inclusions, Neuron 30 (2001) 135-147.
71. N.P. Bajaj, S.T. Al-Sarraj, V. Anderson, M. Kibble, N. Leigh, C.C. Miller, Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis, Neurosci. Lett. 245 (1998) 45-48.
72. H. Yamaguchi, K. Ishiguro, T. Uchida, A. Takashima, C.A. Lemere, K. Imahori, Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II, Acta Neuropathol. (Berl.) 92 (1996) 232-241.
73. J.J. Pei, I. Grundke-Iqbal, K. Iqbal, N. Bogdanovic, B. Winblad, R.F. Cowburn, Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration, Brain Res. 797 (1998) 267-277.
74. J.P. Brion, A.M. Couck, Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5, Am. J. Pathol. 147 (1995) 1465-1476.
75. S.L. Green, P.R. Vulliet, M.J. Pinter, L.C. Cork, Alterations in cyclin-dependent protein kinase 5 (Cdk5) protein levels, activity and immunocytochemistry in canine motor neuron disease, J. Neuropathol. Exp. Neurol. 57 (1998) 1070-1077.
76. G.N. Patrick, L. Zukerberg, M. Nikolic, S. De La Monte, P. Dikkes, L.H. Tsai, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature 402 (1999) 615-622.
77. M.S. Lee, Y.T. Kwon, M. Li, J. Peng, R.M. Friedlander, L.H. Tsai, Neurotoxicity induces cleavage of p35 to p25 by calpain, Nature 405 (2000) 360-364.
78. M.K. Ahlijanian, N.X. Barrezueta, R.D. Williams, A. Jakowski, K.P. Kowsz, S. McCarthy, T. Coskran, A. Carlo, P.A. Seymour, J.E. Burkhardt, R.B. Nelson, J.D. McNeish, Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of Cdk5, Proc. Natl. Acad. Sci. USA 97 (2000) 2910-2915.
79. F. Bian, R. Nath, G. Sobocinski, R.N. Booher, W.J. Lipinski, M.J. Callahan, A. Pack, K.K. Wang, L.C. Walker, Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice, J. Comp. Neurol. 446 (2002) 257-266.
80. A. Pramatarova, J. Laganiere, J. Roussel, K. Brisebois, G.A. Rouleau, Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment, J. Neurosci. 21 (2001) 3369-3374.
81. M.M. Lino, C. Schneider, P. Caroni, Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease, J. Neurosci. 22 (2002) 4825-4832.
82. T. Kawamata, H. Akiyama, T. Yamada, P.L. McGeer, Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue, Am. J. Pathol. 140 (1992) 691-707.
83. D. Troost, N. Claessen, J.J. Van Den Oord, D.F. Swaab, J.M. De Jong, Neuronophagia in the motor cortex in amyotrophic lateral sclerosis, Neuropathol. Appl. Neurobiol. 19 (1993) 390-397.
84. A. Hirano, Neuropathology of ALS: An overview, Neurology 47 (1996) S63-S66.
85. D. Schiffer, S. Cordera, P. Cavalla, A. Migheli, Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis, J. Neurol. Sci. 139 (Suppl) (1996) 27-33.
86. E.D. Hall, J.A. Oostveen, M.E. Gurney, Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS, Glia 23 (1998) 249-256.
87. G. Almer, S. Vukosavic, N. Romero, S. Przedborski, Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis, J. Neurochem. 72 (1999) 2415-2425.
88. M.D. Nguyen, J.P. Julien, S. Rivest, Innate immunity: The missing link in neuroprotection and neurodegeneration? Nat. Rev. Neurosci. 3 (2002) 216-227.
89. M.D. Nguyen, J.P. Julien, S. Rivest, Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: No requirement for proapoptotic interleukin-1 beta in neurodegeneration, Ann. Neurol. 50 (2001) 630-639.
90. V.M. Lee, M. Goedert, J.Q. Trojanowski, Neurodegenerative tauopathies, Annu. Rev. Neurosci. 24 (2001) 1121-1159.
91. K. Stamer, R. Vogel, E. Thies, E. Mandelkow, E.M. Mandelkow, Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress, J. Cell Biol. 156 (2002) 1051-1063.
92. T. Ishihara, M. Hong, B. Zhang, Y. Nakagawa, M.K. Lee, J.Q. Trojanowski, V.M. Lee, Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform, Neuron 24 (1999) 751-762.
93. T. Ishihara, M. Higuchi, B. Zhang, Y. Yoshiyama, M. Hong, J.Q. Trojanowski, V.M. Lee, Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments, J. Neurosci. 21 (2001) 6026-6035.
94. C.J. Echeverri, B.M. Paschal, K.T. Vaughan, R.B. Vallee, Molecular characterization of the 50-kD subunit of dynactin reveals function for the complex in chromosome alignment and spindle organization during mitosis, J. Cell Biol. 132 (1996) 617-633.
95. S.J. King, T.A. Schroer, Dynactin increases the processivity of the cytoplasmic dynein motor, Nat. Cell Biol. 2 (2000) 20-24.
96. D.M. Eckley, S.R. Gill, K.A. Melkonian, J.B. Bingham, H.V. Goodson, J.E. Hauser, T.A. Schroer, Analysis of dynactin subcomplexes reveals a novel actin-related protein associated with the arp1 minifilament pointed end, J. Cell Biol. 147 (1999) 307-320.
97. B.H. LaMonte, K.E. Wallace, B.A. Holloway, S.S. Shelly, J. Ascano, M. Tokito, T. Van Winkle, D.S. Howland, E.L. Holzbaur, Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration, Neuron 34 (2002) 715-727.
98. L.P. Rowland, N.A. Shneider, Amyotrophic lateral sclerosis, N. Engl. J. Med. 344 (2001) 1688-1700.
99. M.E. Gurney, F.B. Cutting, P. Zhai, A. Doble, C.P. Taylor, P.K. Andrus, E.D. Hall, Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis, Ann. Neurol. 39 (1996) 147-157.
100. M.E. Gurney, T.J. Fleck, C.S. Himes, E.D. Hall, Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis, Neurology 50 (1998) 62-66.
101. M. Li, V.O. Ona, C. Guegan, M. Chen, V. Jackson-Lewis, L.J. Rews, A.J. Olszewski, P.E. Stieg, J.P. Lee, S. Przedborski, R.M. Friedlander, Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model, Science 288 (2000) 335-339.
102. P. Klivenyi, R.J. Ferrante, R.T. Matthews, M.B. Bogdanov, A.M. Klein, O.A. Andreassen, G. Mueller, M. Wermer, R. Kaddurah-Daouk, M.F. Beal, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis, Nat. Med. 5 (1999) 347-350.
103. P. Barneoud, O. Curet, Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis, Exp. Neurol. 155 (1999) 243-251.
104. L. Van Den Bosch, P. Tilkin, G. Lemmens, W. Robberecht, Minocycline delays disease onset and mortality in a transgenic model of ALS, Neuroreport 13 (2002) 1067-1070.
105. S. Zhu, I.G. Stavrovskaya, M. Drozda, B.Y. Kim, V. Ona, M. Li, S. Sarang, A.S. Liu, D.M. Hartley, C. Wu Du, S. Gullans, R.J. Ferrante, S. Przedborski, B.S. Kristal, R.M. Friedlander, Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice, Nature 417 (2002) 74-78.
106. J. Kriz, M.D. Nguyen, J.P. Julien, Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis, Neurobiol. Dis. 10 (2002) 268-278.
107. T.M. Tikka, N.E. Vartiainen, G. Goldsteins, S.S. Oja, P.M. Andersen, S.L. Marklund, J. Koistinaho, Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease, Brain 125 (2002) 722-731.
108. O.A. Andreassen, A. Dedeoglu, R.J. Ferrante, B.G. Jenkins, K.L. Ferrante, M. Thomas, A. Friedlich, S.E. Browne, G. Schilling, D.R. Borchelt, S.M. Hersch, C.A. Ross, M.F. Beal, Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease, Neurobiol. Dis. 8 (2001) 479-491.
109. V. Kostic, V. Jackson-Lewis, F. De Bilbao, M. Dubois-Dauphin, S. Przedborski, Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis, Science 277 (1997) 559-562.
110. R.M. Friedlander, R.H. Brown, V. Gagliardini, J. Wang, J. Yuan, Inhibition of ICE slows ALS in mice, Nature 388 (31) (1997).
111. F. Facchinetti, M. Sasaki, F.B. Cutting, P. Zhai, J.E. MacDonald, D. Reif, M.F. Beal, P.L. Huang, T.M. Dawson, M.E. Gurney, V.L. Dawson, Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis, Neuroscience 90 (1999) 1483-1492.
112. C.T. Kuntz, Y. Kinoshita, M.F. Beal, L.A. Donehower, R.S. Morrison, Absence of p53: No effect in a transgenic mouse model of familial amyotrophic lateral sclerosis, Exp. Neurol. 165 (2000) 184-190.